Shenzhen Binde Biotechnology Co., Ltd.

Shenzhen Binde Biotechnology specializes in immune cell-based therapies for cancer. The company has a robust pipeline with at least eight oncology programs spanning from discovery to phase II clinical trials. Its lead program—Mesothelin-targeted CAR-T—is in phase II for stomach cancer. Another key asset targeting PD‑1 for neoplasms has also reached phase II. The company leverages advanced proprietary platforms for both CAR-T and TCR-T therapies, with strong government support and collaborations with the Chinese Academy of Sciences as well as major hospitals across China. Clinical results indicate promising efficacy signals but no published pivotal data yet.